Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Recent developments in the legal battle over the planned $3.3 billion UnitedHealth Group (NYSE: UHG) acquisition of Amedisys (Nasdaq: AMED) have moved the ...

UnitedHealth Group said in a court filing it is working with Amedisys to identify potential buyers for at least 128 home ...

Amedisys has a 1-year low of $82.15 and a 1-year high of $98.95. The company has a market cap of $3.03 billion, a PE ratio of 36.71, a price-to-earnings-growth ratio of 1.82 and a beta of 0.73.

Two whistleblowers have adequately alleged that Amedisys Inc. violated the False Claims Act by improperly billing Medicare and other federal health-care programs for home health services, a New York ...

UnitedHealth Group says the Justice Department’s antitrust challenge to its proposed $3.3 billion purchase of Amedisys is wrong on the merits and threatens to deprive consumers of benefits from ...

UnitedHealth Group says the Justice Department’s antitrust challenge to its proposed $3.3 billion purchase of Amedisys is wrong ... hospice and home care business, the two companies argue ...